Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06939283 | A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma | PHASE1 | ACTIVE NOT_RECRUITING | 100 | — | — | May 7, 2025 | Aug 1, 2028 | Feb 10, 2026 | 5 | United States |
| NCT05678998 | WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma | PHASE1 | COMPLETED | 25 | — | — | Dec 6, 2022 | Feb 5, 2025 | Jan 6, 2026 | 9 | United States |
RECIST = Response Evaluation Criteria in Solid Tumors
| Arm | Type | Description |
|---|---|---|
| Dose- and Regimen Finding | EXPERIMENTAL | Regimen 1 Fixed Dose for 28 days then Regimen 2 Step-up Dose for 28 days |
| Dose Expansion Arm A | EXPERIMENTAL | n\~20 Patients with locally advanced or metastatic cutaneous malignant melanoma who have been treated with a standard of care (SOC) checkpoint inhibitor (CPI) regimen and who demonstrate primary or secondary resistance to this therapy |
| Dose Expansion Arm B | EXPERIMENTAL | n\~20 Patients with locally advanced or metastatic microsatellite-stable (MSS) colorectal carcinoma (CRC) who have progressed on or are intolerant of SOC therapies and who are naïve to immunotherapy |
| Dose Expansion Arm C | EXPERIMENTAL | n\~20 Patients with advanced NHL who are relapsed/refractory to SOC therapies and who are CPI naïve |
| WTX-330 dose escalation | EXPERIMENTAL | Patients with relapsed/refractory advanced or metastatic solid tumors |
| WTX-330 dose expansion in patients for whom CPI therapy is indicated (Arm A) | EXPERIMENTAL | WTX-330 dose expansion in patients with tumor types for which a CPI is indicated/approved who demonstrate primary or secondary resistance to an anti-PD(L)1-based regimen |
| WTX-330 dose expansion in patients for whom CPI therapy is not indicated (Arm B) | EXPERIMENTAL | WTX-330 dose expansion in patients with tumor types for which a CPI is not indicated/ approved |
| Name | Type | Description |
|---|---|---|
| WTX-330 | DRUG | Investigational Product |
Inclusion Criteria: 1. Age ≥ 18 years, 2. Dose escalation (Part 1): Patients with relapsed/refractory locally advanced or metastatic solid tumor for which the patient has progressed on or is intolerant of standard therapy, or for whom no standard therapy with proven benefit exists. Patients with ca...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |